Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Endometrial Neoplasms 1

Interventions

entrectinib 2atezolizumab 2alectinib 2venetoclax 1pertuzumab 1obinutuzumab 1ibrutinib 1etoposide phosphate 1enzalutamide 1cobimetinib 1capmatinib 1acalabrutinib 1Vincristine 1Vemurafenib 1Trastuzumab 1Specimen Handling 1Rituximab 1Radiotherapy 1Prednisone 1Positron-Emission Tomography 1Nivolumab 1Genetic Testing 1Genetic Counseling 1Follow-Up Studies 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Chromatin Immunoprecipitation Sequencing 1CA-4948 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoproliferative Disorders × Biological Assay × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡